T2 Biosystems Inc. (NASDAQ:TTOO) saw an upside of 3.78% to close Tuesday at $0.87 after adding $0.03 on the day. The 5-day average trading volume is 1,240,040 shares of the company’s common stock. It has gained $0.8889 in the past week. An average of 2,230,705 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,716,510.
TTOO’s 1-month performance is -12.10% or -$0.2002 on its low of $0.8350 reached on 10/11/21. The company’s shares have touched a 52-week low of $0.83 and high of $3.79, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, TTOO has lost -29.85% or -$0.3702. However, the current price is down -77.05%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jul 01, 104 days have gone by since the last insider trading activity for T2 Biosystems Inc. (TTOO). McDonough John (Director) most recently sold 18,182 shares at $1.16 per share on Jul 01. This transaction cost the insider $21,091. General Counsel, Gibbs Michael Terrence, sold 8,758 shares at a price of $1.56 on Mar 25. Then, on Mar 17, Chief Commercial Officer Pare Anthony sold 9,620 shares at a price of $1.84 per share. This transaction amounted to $17,701.
T2 Biosystems Inc. (TTOO) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.19 for the sector.TTOO stock has a beta of 0.24. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.47 while the price-to-book (PB) in the most recent quarter is 14.50.
T2 Biosystems Inc.’s quick ratio for the period ended June 29 was 6.30, with the current ratio over the same period at 6.80 meaning that TTOO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 5.17, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 6.60%. The trailing 12-month EBITDA margin is -204.31%. The firm’s gross profit as reported stood at -$3.15 million against revenue of $18.13 million.
For the quarterly period ending June 29 this year, T2 Biosystems Inc.’s cash and short-term investments amounted to $20.08 million against total debt of $57.62 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected TTOO to announce -$0.08 per share in earnings in its latest quarter, but it posted -$0.08, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$10.15 million. TTOO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 69.89 million, with total debt at $57.62 million. Shareholders hold equity totaling $165.85 million
Let’s look briefly at T2 Biosystems Inc. (TTOO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 41.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 40.13%.
The stock’s 5-day moving average is $0.8566, reflecting a -0.69% or -$0.0060 change from its current price. TTOO is currently trading -18.71% above its 20-day SMA, -23.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -18.71% and -25.02% respectively.
Stochastic %K and %D was 6.34% and 4.24% and the average true range (ATR) pointed at 0.0527. The RSI (14) points at 42.73%, while the 14-day stochastic is at 14.20% with the period’s ATR at 0.0568. The stock’s 9-day MACD Oscillator is pointing at -0.0248 and -0.0560 on the 14-day charts.
In the most recent analyst report for T2 Biosystems Inc. (NASDAQ: TTOO), Alliance Global Partners downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for TTOO stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate TTOO as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is TTOO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.25 and a high of $3.00, with their median price target at $2.50. Looking at these predictions, the average price target given by analysts is for T2 Biosystems Inc. (TTOO) stock is $2.31.